DL-Cystein hydrochloride hydrate
Need Assistance?
  • US & Canada:
    +
  • UK: +

DL-Cystein hydrochloride hydrate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
DL-Amino Acids
Catalog number
BAT-007652
CAS number
116797-51-4
Molecular Formula
C3H7NO2S·HCl·H2O
Molecular Weight
175.64
DL-Cystein hydrochloride hydrate
IUPAC Name
2-amino-3-sulfanylpropanoic acid;hydrate;hydrochloride
Alternative CAS
96998-61-7
Synonyms
DL-Cys-OH HCl H2O; 2-Amino-3-mercaptopropanoic acid hydrochloride hydrate; DL-Cysteine HCl Monohydrate; DL-Cysteine HCl H2O; 2-amino-3-sulfanylpropanoic acid;hydrate hydrochloride; H-DL-Cys-OH HCl Monohydrate; DL Cys OH HCl H2O
Related CAS
10318-18-0 (hydrochloride) 3374-22-9 (free base)
Appearance
White Crystals or Crystalline Powder
Purity
≥ 98%
Melting Point
109 °C
Boiling Point
389.7 °C at 760 mmHg
Storage
Store at 2-8 °C
InChI
InChI=1S/C3H7NO2S.ClH.H2O/c4-2(1-7)3(5)6;;/h2,7H,1,4H2,(H,5,6);1H;1H2
InChI Key
QIJRTFXNRTXDIP-UHFFFAOYSA-N
Canonical SMILES
C(C(C(=O)O)N)S.O.Cl
1. Cystinuria: clinical practice recommendation
Aude Servais, et al. Kidney Int. 2021 Jan;99(1):48-58. doi: 10.1016/j.kint.2020.06.035. Epub 2020 Sep 9.
Cystinuria (OMIM 220100) is an autosomal recessive hereditary disorder in which high urinary cystine excretion leads to the formation of cystine stones because of the low solubility of cystine at normal urinary pH. We developed clinical practice recommendation for diagnosis, surgical and medical treatment, and follow-up of patients with cystinuria. Elaboration of these clinical practice recommendations spanned from June 2018 to December 2019 with a consensus conference in January 2019. Selected topic areas were chosen by the co-chairs of the conference. Working groups focusing on specific topics were formed. Group members performed systematic literature review using MEDLINE, drafted the statements, and discussed them. They included geneticists, medical biochemists, pediatric and adult nephrologists, pediatric and adult urologists experts in cystinuria, and the Metabolic Nephropathy Joint Working Group of the European Reference Network for Rare Kidney Diseases (ERKNet) and eUROGEN members. Overall 20 statements were produced to provide guidance on diagnosis, genetic analysis, imaging techniques, surgical treatment (indication and modalities), conservative treatment (hydration, dietetic, alkalinization, and cystine-binding drugs), follow-up, self-monitoring, complications (renal failure and hypertension), and impact on quality of life. Because of the rarity of the disease and the poor level of evidence in the literature, these statements could not be graded. This clinical practice recommendation provides guidance on all aspects of the management of both adults and children with cystinuria, including diagnosis, surgery, and medical treatment.
2. Cystinuria
Aditya Mattoo, David S Goldfarb Semin Nephrol. 2008 Mar;28(2):181-91. doi: 10.1016/j.semnephrol.2008.01.011.
Cystinuria is an inherited disorder characterized by the impaired reabsorption of cystine in the proximal tubule of the nephron and the gastrointestinal epithelium. The only clinically significant manifestation is recurrent nephrolithiasis secondary to the poor solubility of cystine in urine. Although cystinuria is a relatively common disorder, it accounts for no more than 1% of all urinary tract stones. Thus far, mutations in 2 genes, SLC3A1 and SLC7A9, have been identified as being responsible for most cases of cystinuria by encoding defective subunits of the cystine transporter. With the discovery of mutated genes, the classification of patients with cystinuria has been changed from one based on phenotypes (I, II, III) to one based on the affected genes (I and non-type I; or A and B). Most often this classification can be used without gene sequencing by determining whether the affected individual's parents have abnormal urinary cystine excretion. Clinically, insoluble cystine precipitates into hexagonal crystals that can coalesce into larger, recurrent calculi. Prevention of stone formation is the primary goal of management and includes hydration, dietary restriction of salt and animal protein, urinary alkalinization, and cystine-binding thiol drugs.
3. Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review
Marco A Chessa, et al. Dermatol Ther (Heidelb). 2020 Feb;10(1):15-27. doi: 10.1007/s13555-019-00338-x. Epub 2019 Nov 20.
Nail plate brittleness (or fragility) is a common complaint affecting up to 20% of the population, especially women over 50 years of age, with fingernail fragility being more prevalent than toenail fragility. Nail brittleness is characterized by nails that split, flake and crumble, become soft and lose elasticity. The main clinical presentations are: onychoschizia, onychorrhexis, superficial granulation of keratin and worn-down nails. According to causative factors, we can distinguish 2 forms of nail fragility (NF): a primary "idiopathic or brittle nail syndrome" form and NF secondary to different causes such as inflammatory nail disorders, infections, systemic diseases and general conditions, traumas and alteration of the nail hydration. Optimal management requires treatment of the primary cause of brittle nails, when possible. In idiopathic NF oral supplementation, vitamins (especially biotin, also known as vitamin B7), trace elements and amino acids (especially cysteine) have been reported to be useful. In addition, several products, such as topical moisturizers and lacquers could be considered to restructure the affected nail plate and to reduce psychological impacts of this common problem.
Online Inquiry
Verification code
Inquiry Basket